11.1 Safety Communications, Reconciliation and Follow-Up
Key Takeaways
Authority, ethics and investigator reporting channels can have different applicable requirements.
Cumulative safety findings may require rapid communication beyond individual SUSAR cases.
Common data concepts should reconcile, with justified differences documented.
Safety Communications, Reconciliation and Follow-Up
CRAs and clinical data managers conduct rigorous SAE reconciliation between these two systems:
- Term Congruence: Check whether both systems describe the same clinical event. Different structures, coding versions or levels of detail may be legitimate when documented and reconciled.
- Date Matching: The date of event onset, date of site awareness, and date of event resolution should agree where they represent the same concept, with justified differences documented.
- Criteria Alignment: The seriousness criteria checked on the eCRF (e.g., hospitalization) must match the criteria registered in the pharmacovigilance system.
- Severity and Causality: Both systems must reflect the investigator's recorded assessment of severity and causality with any justified difference explained.
Cross-Referencing Source Notes for Timeliness Compliance
The CRA reviews appropriate records and communications to evaluate immediate reporting and the actual protocol-defined deadline:
- Compare the date and time on hospital admission notifications or clinical progress notes against the transmission timestamp on the initial SAE notification form sent to the sponsor.
- For example, a protocol requiring initial notification within 24 hours would not be met by awareness on Monday at 09:00 and initial transmission Thursday at 16:00. Evaluate any permitted exception, participant impact and the reporting process; classify the finding under the trial’s method. The CRA documents the deviation in the monitoring report, reviews it during the investigator debriefing, and ensures an appropriate CAPA is executed.
Safety communications and signal evaluation
Follow the distribution plan and applicable reporting requirements for safety notifications to investigators and IRBs/IECs. Authority reporting deadlines do not automatically establish an identical ethics committee deadline. Confirm investigator receipt and review, assess whether the information affects consent or protocol conduct, and preserve the communication in the appropriate file. An ISF section number is a sponsor filing convention, not a universal rule.
Pharmacovigilance combines individual case assessment with cumulative review. Expected serious reactions, increased event rates, lack of efficacy in a life-threatening disease, and major new nonclinical findings can require rapid communication even without a new individual SUSAR. E2A explicitly recognises these other observations. A classification algorithm supports judgement; it does not replace medical and scientific evaluation.
A Data Monitoring Committee (DMC/IDMC/DSMB) may recommend continuation, modification or stopping after reviewing safety and relevant efficacy data. Its charter defines composition, access, schedule and decision process. Not every trial requires a DMC, and safety concerns need not reach statistical significance before action. The sponsor documents its response; the CRA verifies site implementation while maintaining the blind for personnel who should not receive treatment identities.
Comparing reporting channels
| Route | Trigger and governing instruction | Timing |
|---|---|---|
| Investigator to sponsor | SAE; protocol-defined exceptions may apply | Immediately after reasonable awareness; use the actual protocol deadline |
| Sponsor to authority | Fatal/life-threatening unexpected suspected reaction | As soon as possible, within 7 calendar days; follow-up within 8 additional days |
| Sponsor to authority | Other serious unexpected suspected reaction | As soon as possible, within 15 calendar days after minimum criteria are met |
| Investigator/sponsor to IRB/IEC | Safety information and changes required by the applicable framework | Follow applicable requirements and committee procedures |
| DMC to sponsor | Safety/efficacy review and recommendations | Charter schedule and urgent procedures |
The clocks serve different purposes. A site cannot wait 15 days to notify the sponsor merely because a sponsor authority report may have a 15-day maximum. A sponsor cannot postpone a qualifying expedited report until the next DMC meeting. Keep awareness dates, initial transmissions, follow-up and receipt acknowledgements traceable.
Stopping treatment and leaving a trial are different decisions
A participant may stop the investigational product, discontinue an assessment, withdraw consent for some activities or leave all further trial follow-up. These outcomes should not be collapsed into a single checkbox. E6(R3) expects protocol-based handling of the end of participation, respectful communication and appropriate care. Reliable records describe what the person decided and what the investigator determined, including the scope of any continuing permission.
A protocol may require permanent discontinuation for a safety finding, allow a temporary hold, or permit continued outcome follow-up after product cessation. The investigator makes the clinical decision within the protocol and applicable requirements. The CRA verifies the evidence, authorised process and reporting; they do not unilaterally stop treatment or insist on continued participation to protect a study endpoint.
Reconciling dates without erasing their meaning
An event can begin before admission, be reported to the investigator later and reach the sponsor on another date. Those dates need not equal one another. Reconcile each field to its defined concept and supporting evidence. If two systems intentionally collect different concepts, document the mapping rather than forcing equality. If they collect the same onset date and disagree, obtain supported clarification. The investigator and sponsor can also have different causality assessments; preserve each assessment and apply the reporting standard rather than overwriting one opinion to make the databases look identical.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E2A, WMA Declaration of Helsinki, 2024.
Safety and clinical systems use different onset dates for the same event. What should happen?
Delete the safety report to remove the discrepancy.
Assume discharge date must equal onset date.
Verify the source chronology and reconcile the supported concepts through the responsible workflow.
Always copy the later date into every system.
Sections you finish are checked off in the contents.